According to the Centers for Disease Control and Prevention, more than 6.4 million US children 4-17 years old have been diagnosed with attention-deficit/hyperactivity disorder (ADHD). The percentage of US children diagnosed with ADHD has increased by 3-5 percent per year since the 1990s. Relatedly, the percentage of children in this age group taking ADHD medication also has increased by about 7 percent per year from 2007-2008 to 2011-2012.
In response, some state Medicaid programs have implemented policies to manage the use of ADHD medications and guide physicians toward best practices for ADHD treatment in children. These policies include prescription medication prior authorization requirements that restrict approvals to patients above a certain age, or require additional provider involvement before approval for payment is granted.
In a new article published this afternoon in MMWR, CDC researchers compared Medicaid and employer-sponsored insurance (ESI) claims for “psychological services” (the procedure code category that includes behavior therapy) and ADHD medication among children aged 2–5 years receiving clinical care for ADHD.
The article references a newly released LawAtlas map that examines features of state Medicaid prior authorization policies that pertain to pediatric ADHD medication treatment, including applicable ages, medication types, and criteria for approval.
The data from the map show:
- 27 states manage access to ADHD medication for children
- 7 states ask a prescriber whether behavioral therapy or other non-medication treatments have been considered before authorization is granted for ADHD medication prescriptions for children
- 16 states have Medicaid prior-authorization policies that specifically apply to children younger than six years old that require additional prescriber involvement to obtain coverage for ADHD medication
Read the article at MMWR and interact with the data at LawAtlas.org. You may also tune in to a CDC Town Hall meeting on May 10 at 2 p.m. ET where the authors will discuss the MMWR report’s key findings and take questions.